< 生产厂家价格 >

吗替麦考酚酯

吗替麦考酚酯用途

Mycophenolate Mofetil是非竞争性,选择性和可逆的肌苷一磷酸脱氢酶(IMPDH)抑制剂,IC50分别为39 nM 和27 nM。

点击显示

吗替麦考酚酯名称

[ CAS 号 ]:
128794-94-5

[ 中文名 ]:
帕纳替尼

[ 英文名 ]:
Mycophenolate mofetil

[中文别名 ]:

[英文别名 ]:

Cellcept
MYCOPHENOLATE MOFETIL EP IMPURITY A (= USD RC A)
Mycophenolate mofetil (CellCept)
Mycophenolatemofetil
MYCOPHENOLATE MOFITILE
MYCOPHENOLATE
RS 61443-190
MYCOPHENALATE MOFETIL
MYCOPHENOLATE MOFETIL(CELLCEPT)
Mycophenolate mofetil

吗替麦考酚酯生物活性

[ 描述 ]:

Mycophenolate Mofetil是非竞争性,选择性和可逆的肌苷一磷酸脱氢酶(IMPDH)抑制剂,IC50分别为39 nM 和27 nM。

[ 相关类别 ]:

信号通路 >> 其他 >> 其他

研究领域 >> 癌症

[参考文献]

[1]. Nakanishi, T., et al., Effect of the inosine 5'-monophosphate dehydrogenase inhibitor BMS-566419 on rat cardiac allograft rejection. Int Immunopharmacol, 2010. 10(1): p. 91-7.

[2]. Dehghani, F., et al., Inhibition of microglial and astrocytic inflammatory responses by the immunosuppressant mycophenolate mofetil. Neuropathol Appl Neurobiol, 2010. 36(7): p. 598-611.

[3]. Ozgen, M., et al., Mycophenolate mofetil and daclizumab targeting T lymphocytes in bleomycin-induced experimental scleroderma. Clin Exp Dermatol, 2012. 37(1): p. 48-54.

[相关活性小分子]

吗替麦考酚酯物理化学性质

[ 密度 ]:
1.2±0.1 g/cm3

[ 沸点 ]:
637.6±55.0 °C at 760 mmHg

[ 熔点 ]:
95-96ºC

[ 分子式 ]:
C₂₃H₃₁NO₇

[ 分子量 ]:
433.495

[ 闪点 ]:
339.4±31.5 °C

[ 精确质量 ]:
433.210052

[ PSA ]:
94.53000

[ LogP ]:
3.15

[ 外观性状 ]:
白色至灰白色结晶粉末

[ 蒸汽压 ]:
0.0±2.0 mmHg at 25°C

[ 折射率 ]:
1.557

[ 储存条件 ]:
Store at RT

[ 水溶解性 ]:
水溶性：不溶；水溶解度：43 mg/l ；易溶于：丙酮；可溶于：甲醇；极微溶：乙醇

吗替麦考酚酯MSDS

详细MSDS(安全技术说明书)

吗替麦考酚酯安全信息

[ 符号 ]:

GHS07, GHS09

[ 信号词 ]:
Warning

[ 危害声明 ]:
H302-H400

[ 警示性声明 ]:
P273

[ 危害码 (欧洲) ]:
Xn

[ 风险声明 (欧洲) ]:
R22

[ 安全声明 (欧洲) ]:
22

[ 危险品运输编码 ]:
UN 3077 9 / PGIII

吗替麦考酚酯文献

Safety and efficacy of the early introduction of everolimus with reduced-exposure cyclosporine a in de novo kidney recipients.

Transplantation 99(1) , 180-6, (2015)

Everolimus and cyclosporine A (CsA) exhibit synergistic immunosuppressive activity when used in combination. We examined the safety and efficacy of the use of everolimus with a cyclosporine-sparing st...

Preemptive thoracic drainage to eradicate postoperative pulmonary complications after living donor liver transplantation.

J. Am. Coll. Surg. 219(6) , 1134-42.e2, (2014)

Thoracic fluid retention after living donor liver transplantation (LDLT) has various negative consequences, including atelectasis, pneumonia, and respiratory distress or failure.We analyzed the clinic...

The risk of recurrent IgA nephropathy in a steroid-free protocol and other modifying immunosuppression.

Clin. Transplant. 28(8) , 845-54, (2014)

Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and o...

更多文献